Novacyt S.A. (NCYT.L)

GBp 50.8

(-1.36%)

Market Cap (In GBp)

35.87 Million

Revenue (In GBp)

11.57 Million

Net Income (In GBp)

-28.29 Million

Avg. Volume

650.89 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
42.95-137.0
PE
-
EPS
-
Beta Value
-1.775
ISIN
FR0010397232
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Lyn Dafydd Rees
Employee Count
-
Website
https://www.novacyt.com
Ipo Date
2017-11-01
Details
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.